Orphan Europe was founded in 1990 to provide treatments for people with a rare disease. Orphan Europe was acquired by Recordati in 2007. Recordati is an international pharmaceutical company listed on the Italian stock exchange and has over 3,300 staff dedicated to the research, development, manufacturing and marketing of pharmaceuticals.

Teva is committed to increasing access to high-quality healthcare for people across the globe, at every stage of life. Teva does this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

The company’s line of generic and specialty treatments is backed by its impressive global development and manufacturing capabilities, ensuring the highest quality and accessibility to medicines while reducing costs. Teva’s participation in a wide range of therapeutic areas and dosage forms is empowered by a unique integration of innovative specialty and generic research.